Overview
PDS Biotech’s pipeline combines Versamune® technology with disease-specific antigens in both the development of cancer immunotherapies and infectious disease vaccines.
Product | Indication | Combination | PC | P1 | P2 | P3 | R | PARTNER(S) | |
---|---|---|---|---|---|---|---|---|---|
Oncology | |||||||||
PDS0101 (HPV16) |
First line treatment of recurrent / metastatic head and neck cancer Learn more |
KEYTRUDA® |
|
|
![]() |
||||
|
|||||||||
PDS0101 (HPV16) |
Advanced HPV-associated malignancies Learn more |
M7824 |
|
|
![]() |
||||
|
|||||||||
PDS0101 (HPV16) |
Stage Ilb-IVa cervical cancer Learn more |
Chemo-radiation |
|
|
![]() |
||||
|
|||||||||
PDS0102 (TARP) |
Prostate and breast cancer | Immunotherapy |
|
|
![]() |
||||
|
|||||||||
PDS0103 (MUC-1) |
Breast, colorectal, ovarian and NSCLC cancer | Immunotherapy |
|
|
![]() |
||||
|
|||||||||
PDS0104 (TRP2) |
Melanoma | Immunotherapy |
|
|
|||||
|
|||||||||
PDS Biotech Funded ![]() |
Partner Co-Funded ![]() |